Low adherence with antihypertensives in actual practice: the association with social participation -- a multilevel analysis

Johnell, Kristina; Råstam, Lennart; Lithman, Thor; Sundquist, Jan; Merlo, Juan
January 2005
BMC Public Health;2005, Vol. 5 Issue 1, p17
Academic Journal
Background: Low adherence is a key factor in explaining impaired effectiveness and efficiency in the pharmacological treatment of hypertension. However, little is known about which factors determine low adherence in actual practice. The purpose of this study is to examine whether low social participation is associated with low adherence with antihypertensive medication, and if this association is modified by the municipality of residence. Methods: 1288 users of antihypertensive medication were identified from The Health Survey in Scania 2000, Sweden. The outcome was low adherence with antihypertensives during the last two weeks. Multilevel logistic regression with participants at the first level and municipalities at the second level was used for analyses of the data. Results: Low social participation was associated with low adherence with antihypertensives during the last two weeks (OR = 2.05, 95% CI: 1.05-3.99), independently of low educational level. However, after additional adjustment for poor self-rated health and poor psychological health, the association between low social participation and low adherence with antihypertensives during the last two weeks remained but was not conclusive (OR = 1.80, 95% CI: 0.90-3.61). Furthermore, the association between low social participation and low adherence with antihypertensives during the last two weeks varied among municipalities in Scania (i.e., cross-level interaction). Conclusion: Low social participation seems to be associated with low adherence with antihypertensives during the last two weeks, and this association may be modified by the municipality of residence. Future studies aimed at investigating health-related behaviours in general and low adherence with medication in particular might benefit if they consider area of residence.


Related Articles

  • Defining, Treating Borderline Hypertension Continues to Challenge Clinicians, Researchers. Marwick, Charles // JAMA: Journal of the American Medical Association;8/14/91, Vol. 266 Issue 6, p767 

    Discusses research on borderline hypertension, an asymptomatic disease. Definition of the disease; Ways to prevent the disease without drug therapy; Factors to consider in managing hypertension.

  • Dose escalation of a curcuminoid formulation. Lao, Christopher D.; Ruffin IV, Mack T.; Normolle, Daniel; Heath, Dennis D.; Murray, Sandra I.; Bailey, Joanne M.; Boggs, Martha E.; Crowell, James; Rock, Cheryl L.; Brenner, Dean E. // BMC Complementary & Alternative Medicine;2006, Vol. 6, p10 

    Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been...


    The aim of the present review is to summarise, classify and outline the benefits and disadvantages of the models for reproducing osteoarthritis, most commonly used in experimental veterinary orthopaedics (spontaneous, chemical and physical). The potential for application of a given experimental...

  • ACE/CCB or ACE/HCTZ for HTN: Which is better?  // Primary Care Reports;Feb2009 Clinical Briefs in Primary, Vol. 14 Issue 2, p4 

    This article discusses research being done on the use of the combined Benazepril and amlodipine or hydrochlorothiazide for treatment of hypertension in high risk patients. It references a study by K. Jamerson et al published in the 2008 issue of "National English Journal of Medicine." The study...

  • Hepatoprotective activity of Sonchus asper in paracetamol-induced hepatic damage in rabbits. Aftab-Ullah; Ahmad, Mahmood; Ahmad, Taseer; Naseer, Faiza // Bangladesh Journal of Pharmacology;2015, Vol. 10 Issue 1, p115 

    No abstract available.

  • Reading the Tea Leaves: Anticarcinogenic Properties of (-)-Epigallocatechin-3-Gallate. Carlson, Jennifer R.; Bauer, Brent A.; Vincent, Ann; Limburg, Paul J.; Wilson, Ted // Mayo Clinic Proceedings;Jun2007, Vol. 82 Issue 6, p725 

    Green tea is an extremely popular beverage worldwide. Derivatives of green tea, particularly (-)-epigallocatechin-3-gallate (EGCG), have been proposed to have anticarcinogenic properties based on preclinical, observational, and clinical trial data. To summarize, clarify, and extend current...

  • Milk Products Containing Bioactive Tripeptides Have an Antihypertensive Effect in Double Transgenic Rats (dTGR) Harbouring Human Renin and Human Angiotensinogen Genes. Jauhiainen, Tiina; Pilvi, Taru; Zhong Jian Cheng; Kautiainen, Hannu; Müller, Dominik N.; Vapaatalo, Heikki; Korpela, Riitta; Mervaala, Eero // Journal of Nutrition & Metabolism;2010, p1 

    Tripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) act as ACE inhibitors in vitro. Double transgenic rats (dTGR) harbouring human renin and human angiotensinogen genes developmalignant hypertension due to increased angiotensin II formation. The present study was aimed to...

  • Comparative study of Heart Rate Variability in normotensive offsprings of hypertensive parents. Chinagudi, Surekharani; Herur, Anita; Patil, Shailaja; Shashikala, C. V.; Roopa, A. // Biomedical Research (0970-938X);2013, Vol. 24 Issue 1, p123 

    Hypertension or prehypertension are the diseases which affect entire body. Many times there would have been organ damage even before the diagnosis of hypertension. So it becomes very essential to diagnose hypertension or rather prehypertension at an early stage so that the preventive measures...

  • Could hypertension be treated with a vaccine?  // GP: General Practitioner;3/21/2008, p14 

    The article reports on the research being done for the development of a vaccine that will boosts hypertension treatment. In a study, the vaccine has been shown to be safe and effective in health. According to Martin Bachmann, chief scientific officer of Cytos Bio-technology AG, the study aims at...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics